Wall Street Thinks This Weight Loss Drug Stock Could More Than 3X Over the Next 12 Months -- and It's Not Eli Lilly or Novo Nordisk
Few big pharma stocks have been bigger winners over the last three years than Eli Lilly and Novo Nordisk. Lilly now ranks as the largest drugmaker in the world, with a market cap of $844 billion, after its shares skyrocketed more than 270%. Novo Nordisk stock is up around 75% despite a pullback in recent months.
There's no secret to their success: Both companies have blockbuster weight-loss drugs. But the obesity market could soon have a new contender. Wall Street thinks this weight-loss drug stock could more than 3x over the next 12 months -- and it's not Eli Lilly or Novo Nordisk.
Viking Therapeutics' (NASDAQ: VKTX) share price currently hovers around $32. The average analysts' 12-month price target for the biotech stock is $99.29 -- more than 200% higher.
The great expectations for Viking Therapeutics aren't limited to only a few outlier analysts, though. Of the 17 analysts surveyed by LSEG in February who cover the stock, seven rated it as a "strong buy." Another nine analysts viewed Viking as a "buy." The remaining analyst recommended holding the stock.
This optimism on Wall Street remains pretty solid despite Viking's less-than-stellar performance over the past few months. The small drugmaker's share price has plunged nearly 60% since late October 2024.
Why the steep decline? Some investors were concerned about the outlook for weight-loss drugs after Donald Trump won a second term as president. Trump appointed Robert F. Kennedy Jr. as Secretary of Health and Human Services, and Kennedy has expressed skepticism in the past about relying on medications to lose weight.
Also, Viking was seen by some as a potential acquisition target for Merck. However, Merck announced in December 2024 it was licensing Hansoh Pharma's obesity drug HS-10535. This move added a new (and potentially formidable) competitor for Viking and greatly reduced the likelihood that Merck would acquire the company.
Why do many Wall Street analysts like Viking Therapeutics so much? It has an especially promising pipeline.
The company's lead pipeline candidate is subcutaneous VK-2735. Viking plans to advance the drug into phase 3 clinical studies in treating obesity in the second quarter of this year. VK-2735 is a dual agonist of the glucagon-like peptide-1 (GLP-1) receptor and the glucose-dependent insulinotropic polypeptide (GIP) receptor. This is the same mechanism of action as Lilly's tirzepatide, which is marketed as Mounjaro in the U.S. for treating type 2 diabetes and as Zepbound for treating obesity.
Viking is also evaluating an oral tablet formulation of VK-2735 in phase 2 testing. The company thinks this tablet could be more attractive for patients who are reluctant to receive injections, or for those trying to maintain weight loss achieved with an injection.
Unlike many clinical-stage biotech companies, though, Viking isn't a one-trick pony. Its pipeline includes another candidate that could soon advance into late-stage studies -- VK-2809. This experimental therapy targets the severe liver disease metabolic dysfunction-associated steatohepatitis (MASH), which is also known as nonalcoholic steatohepatitis (NASH).
As they say on the infomercials, "But wait! There's more!" Viking is also evaluating VK-0214 in a phase 1 clinical trial as a potential treatment for X-linked adrenoleukodystrophy (X-ALD), a rare neurodegenerative disease. There are currently no approved drugs for treating X-ALD.
You shouldn't buy Viking stock solely because Wall Street likes it. Clinical-stage biotech stocks aren't well-suited for risk-averse investors, and Viking is no exception. There's no guarantee that the company's pipeline programs will be successful.
However, I think Viking Therapeutics could be a great pick for aggressive investors. The prospects for VK-2735 and VK-2809 appear to be good based on their phase 2 results. Viking's market cap is below $3.6 billion right now. If either or both of these drugs fulfill their potential, the company should be worth a lot more in a few years.
Ever feel like you missed the boat in buying the most successful stocks? Then you'll want to hear this.
On rare occasions, our expert team of analysts issues a 'Double Down' stock recommendation for companies that they think are about to pop. If you're worried you've already missed your chance to invest, now is the best time to buy before it's too late. And the numbers speak for themselves:
Nvidia: if you invested $1,000 when we doubled down in 2009, you'd have $348,579!*
Apple: if you invested $1,000 when we doubled down in 2008, you'd have $46,554!*
Netflix: if you invested $1,000 when we doubled down in 2004, you'd have $540,990!*
Right now, we're issuing 'Double Down' alerts for three incredible companies, and there may not be another chance like this anytime soon.*Stock Advisor returns as of February 21, 2025
Keith Speights has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Merck. The Motley Fool recommends Novo Nordisk and Viking Therapeutics. The Motley Fool has a disclosure policy.
Wall Street Thinks This Weight Loss Drug Stock Could More Than 3X Over the Next 12 Months -- and It's Not Eli Lilly or Novo Nordisk was originally published by The Motley Fool
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
26 minutes ago
- Yahoo
Liberals under fire for rushing bill through Parliament to speed up resource projects
OTTAWA — Prime Minister Mark Carney's government is coming under fire for seeking to rush through a major piece of legislation that grants cabinet sweeping powers to quickly approve major projects. Government House leader Steven MacKinnon put a motion on notice Thursday that would push Bill C-5 through the House of Commons by the end of next week — leaving just one day to hear from civil society groups, stakeholders and experts. Critics charge the move is anti-democratic. In a fiery exchange in question period, Bloc Québécois House Leader Christine Normandin accused Prime Minister Mark Carney of trying to "steamroll" a bill through the House that would greatly expand his own powers. "The prime minister has no right to impose C-5 under closure when the bill gives him exceptional powers unlike anything that we've seen before," she said in French. "Is that the prime minister's intention, to bypass Parliament and govern by decree like Donald Trump?' MacKinnon pushed back by saying "Canadians and Quebecers spoke loud and clear" in the last election for action to shore up the economy, in part due to the illegal trade war initiated by U.S. President Donald Trump. "We are acting in a democratic way," he said, noting the bill delivers on election promises laid out clearly in the Liberal platform. The bill includes controversial provisions that could allow cabinet to skirt existing processes and laws to fast-track approvals for projects the government deems to be in the national interest. The government aims to streamline disparate processes to limit approval timelines for big projects to a maximum of two years, boosting investor confidence. When asked about the timeline at a press conference Thursday, Energy Minister Tim Hodgson said the legislation needs to pass quickly to shore up an economy being undermined by Trump's tariffs. "We have a trade war that is affecting sector after sector after sector. Canadians' jobs are at risk. Canadians' livelihoods are at risk. And quite frankly, the prosperity of the country is at risk," Hodgson said. But NDP MP Leah Gazan said in the House of Commons foyer Thursday that the bill isn't going to build the economy out because it will trigger a series of court challenges. She called on the government to extend the time frame of the public study and do more to consult with Indigenous Peoples — something she said got shortchanged in the bill. "I'm calling on the prime minister to slow it down, to not rush a bill that has this much consequence through in five days," she said. Hodgson pointed to support for the bill from the First Nations Major Projects Coalition, which represents more than 100 First Nations seeking to have their own projects advanced, and said he is consulting privately with stakeholders. "I can tell you I've got multiple conversations going on with different rights holders and business leaders as part of my department's efforts to ensure that consultation is robust," he said. Indigenous Services Minister Mandy Gull-Masty said there will be a meeting between the Prime Minister's Office and First Nations leaders, citing the wildfires as one reason it has been delayed. "I also want to acknowledge that because there are many communities in a critical state of wildfire and evacuation, that time will be taken to have that dialog," she said. "I know that it is the intention of the Prime Minister's Office to sit down with First Nation's leadership directly and to have the economic discussion and hear from them." But Anna Johnston, staff lawyer at West Coast Environmental Law, said the drive to push the bill through quickly is "incredibly concerning" because the government has done "very little engagement" so far on such a major piece of legislation. "The biggest concern is that it's going to give cabinet the power to approve projects before they have any information about them beyond what the proponent has decided to give the government," she said. "There's a reason why we have decisions at the end of environmental assessments and regulatory processes. It's so that governments can make informed decisions about projects that have the potential to harm Canadians and to harm the environment." Stuart Trew, a senior researcher with the left-leaning think tank Canadian Centre for Policy Alternatives, said the bill is "destined to end up in court" and "really bump up against the government's commitments to reconciliation with First Nations." "It seems geared to let the government ram projects through, without adequate study, without all the usual considerations about the impacts on endangered species," he said. "We should raise our eyebrows any time a government claims a national emergency in order to rush through legislation with implications as significant as this does." The legislation also looks to break down internal trade barriers and make it easier for workers to take jobs in other provinces. MacKinnon rejected a call from the Bloc Québécois this week to split the landmark legislation in two. That would have allowed the House to speed through the less contentious internal trade provisions while putting the controversial major projects portion under the microscope. Carney has vowed repeatedly to eliminate interprovincial trade barriers by Canada Day, 19 days from now. The House has been sitting for just three weeks and is currently scheduled to rise next week on June 20. MacKinnon said in a scrum on Wednesday that he has not tried to get consensus from the other parties to have the House sit any later. This report by The Canadian Press was first published June 12, 2025. Kyle Duggan, The Canadian Press
Yahoo
27 minutes ago
- Yahoo
Quince Therapeutics Announces Pricing of Up to $22 Million Private Placement of Securities
Financing to provide $11.5 million in upfront proceeds with up to an additional $10.4 million of proceeds assuming exercise in full of the warrants Financing priced at a premium to last close SOUTH SAN FRANCISCO, Calif., June 12, 2025--(BUSINESS WIRE)--Quince Therapeutics, Inc. (Nasdaq: QNCX) ("Quince" or the "Company"), a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases, today announced that it has entered into a securities purchase agreement with certain institutional and accredited investors to purchase shares of its common stock (or pre-funded warrants in lieu thereof), and accompanying common warrants ("Warrants") that is expected to result in approximately $11.5 million in upfront proceeds and potential additional proceeds of up to $10.4 million if the accompanying common warrants are exercised in full for cash, before deducting placement agent fees and other private placement expenses. The private placement is being led by healthcare-focused institutional investor Nantahala Capital with participation from existing Quince stockholders including ADAR1 Capital Management, along with members of Quince's senior management. Quince intends to use the net proceeds of this offering for working capital and general corporate purposes, including funding the ongoing enrollment of the Company's pivotal Phase 3 NEAT (Neurological Effects of eDSP on Subjects with A-T; NCT06193200/IEDAT-04-2022) clinical trial in Ataxia-Telangiectasia (A-T), research and development expenses, general and administrative expenses and capital expenditures. The net upfront proceeds from the private placement, combined with Quince's current cash, cash equivalents, and short-term investments are expected to fund the Company's operations into the second quarter of 2026, or the second half of 2026 if the Warrants are exercised in full for cash. At the closing, the Company will issue to the investors an aggregate of 8,671,928 shares of common stock (or pre-funded warrants in lieu thereof), along with accompanying Warrants to purchase an aggregate of 8,671,928 shares of common stock (or pre-funded warrants in lieu thereof), at a combined purchase price of $1.325 per share (or $1.324 per pre-funded warrant) and accompanying Warrant (representing a 10% premium over the $1.20 closing price per share of the Company's common stock). The accompanying Warrants have an exercise price of $1.20 per share and will become exercisable immediately. The Warrants will expire five years from the date of issuance. The private placement is expected to close during the week of June 16, 2025, subject to the satisfaction of customary closing conditions. Citizens Capital Markets is acting as the lead placement agent for the private placement. Maxim Group LLC and Brookline Capital Markets, a division of Arcadia Securities, LLC, are acting as co-placement agents for the private placement. The securities to be issued in connection with the private placement described above are being offered in a private placement and have not been registered under the Securities Act of 1933, as amended (the "Securities Act"), or any state or other applicable jurisdictions' securities laws, and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements of the Securities Act and applicable state or other jurisdictions' securities laws. This news release does not constitute an offer to sell or the solicitation of an offer to buy the securities described herein, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation, or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction. About Quince Therapeutics Quince Therapeutics, Inc. (Nasdaq: QNCX) is a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases. For more information on the company and its latest news, visit Forward-looking Statements Statements made in this news release that are not statements of historical or current facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that statements in this news release regarding the expected closing of the private placement; the receipt of additional gross proceeds if the accompanying common warrants are exercised in full; the achievement of positive clinical trial results and approval of the eDSP by the FDA; the company's intended use of the proceeds from the private placement; the company's expectation that the net proceeds from the closing of the private placement, combined with its current cash, cash equivalents and marketable securities, will fund its operating and capital expenditures into the second quarter of 2026, or the second half of 2026, assuming all warrants are exercised for cash; and the company's strategy, future operations, future financial position, projected expenses, expected timing and results of clinical trials, prospects, plans and objectives of management constitute forward-looking statements that involve risks and uncertainties, including, without limitation, risks and uncertainties related to: cost, timing, progress and results of the pivotal Phase 3 NEAT clinical trial in A-T indication and potential future trials in other indications; the company's ability to obtain FDA approval and successfully commercialize its product candidate; the satisfaction of customary closing conditions related to the proposed private placement and the impact of general economic, industry or political conditions in the United States or internationally, the current or evolving effects of macroeconomic conditions, on Quince's business operations and activities. There can be no assurance that the company will be able to complete the proposed private placement on acceptable terms, or at all. Quince's actual results, performance, or achievements could differ materially from those expressed or implied by the forward-looking statements as a result of a number of factors, including the risks discussed under the heading "Risk Factors" discussed under the caption "Item 1A. Risk Factors" in Part I of Quince's most recent Annual Report on Form 10-K or any updates discussed under the caption "Item 1A. Risk Factors" in Part II of its Quarterly Reports on Form 10-Q and in the company's other filings with the SEC. Quince undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise that occur after that date, except as required by law. View source version on Contacts Media & Investor Contact: Stacy RoughanQuince Therapeutics, President, Corporate Communications & Investor Relationsir@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
28 minutes ago
- Yahoo
Jobless claims data, broadening stock gains: Market Takeaways
US stocks (^DJI, ^IXIC, ^GSPC) closed Thursday's session in positive territory after the latest inflation data and President Trump announcing plans for unilateral tariffs against trade partners. Yahoo Finance senior markets reporter Josh Schafer examines several of the prominent market themes in the trading day, including this week's initial jobless claims and the broadening of the market's outperformance across sectors. To watch more expert insights and analysis on the latest market action, check out more Asking for a Trend here.
